The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Re-sensitizing PD-1/PD-L1 relapsed/refractory solid tumors: Phase 1a results of IOS-1002, a LILRB1/2 and KIR3DL1 checkpoint inhibitor, in combination with pembrolizumab.
 
Stephen Luen
Honoraria - AstraZeneca; Novartis
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Novartis (Inst); Roche (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
Pawan Bajaj
No Relationships to Disclose
 
Prunella Blinman
No Relationships to Disclose
 
Jayesh Desai
Consulting or Advisory Role - Amgen (Inst); Axelia Oncology; Bayer; BeiGene; Boehringer Ingelheim; Daiichi Sankyo Europe GmbH; Ellipses Pharma; GlaxoSmithKline; Incyte; Merck KGaA; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche (Inst)
 
Sophia Frentzas
No Relationships to Disclose
 
Hui Gan
Consulting or Advisory Role - Curis Pharmaceuticals; Curis Pharmaceuticals; Grey Wolf; Merck KGaA; MSD; Servier; Servier; Telix Pharmaceuticals
Speakers' Bureau - Daichii Sankyo
Research Funding - AbbVie
 
Ortis Estacio
No Relationships to Disclose
 
Samuel Harris
No Relationships to Disclose
 
Ben Markman
Consulting or Advisory Role - Greywolf Therapeutics
 
Michael Millward
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; Bristol Myers Squibb Australia; Bristol Myers Squibb Australia; The Limbic
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Albion Laboratories (Inst); Alpine Immune Sciences (Inst); AstraZeneca (Inst); Atavistik Bio (Inst); AtriCure (Inst); Axelia Oncology (Inst); Axelia Oncology (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cullinan Oncology (Inst); D3 Bio (Inst); DualityBio (Inst); Eucure Biopharma (Inst); Genentech/Roche (Inst); Genfleet Therapeutics (Inst); GlaxoSmithKline (Inst); ImmunOs Therapeutics (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); InventisBio (Inst); InxMed (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Maxinovel (Inst); Nuvation Bio (Inst); Pathios Therapeutics (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Synnovation Therapeutics (Inst); Tyra Biosciences (Inst); Vivace Therapeutics (Inst)
 
Catherine Shannon
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; Daiichi Sankyo/Lilly; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; GlaxoSmithKline; Lilly; Lilly; Merck; Merck sharp and Dohme; Novartis; Novartis; Roche
Speakers' Bureau - Amgen; AstraZeneca; AstraZeneca; AstraZeneca; Gilead Sciences; GlaxoSmithKline; GlaxoSmithKline; Lilly; Merck; merk sharp & Dohme; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis
 
Hilmar Ebersbach
Employment - ImmunOs Therapeutics
Leadership - ImmunOs Therapeutics
Stock and Other Ownership Interests - ImmunOs Therapeutics
Patents, Royalties, Other Intellectual Property - ImmunOs Therapeutics
 
Claudia Berger
Employment - Immunos Therapeutics
Leadership - IMUmunos Therapeutics
Stock and Other Ownership Interests - Immunos Therapeutics
Patents, Royalties, Other Intellectual Property - Immunos Therapeutics
 
Christoph Renner
Employment - ImmunOs Therapeutics
Leadership - ImmunOs Therapeutics
Stock and Other Ownership Interests - ImmunOs Therapeutics
Honoraria - Abbvie (Inst); Amgen (Inst); Celgene/Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Sanofi (Inst)
Consulting or Advisory Role - BeiGene (Inst); Roche (Inst)
Speakers' Bureau - Abbvie (Inst); Amgen (Inst)
Patents, Royalties, Other Intellectual Property - Roylaties from HUMANIGEN for GM.CSF antibody. Royalties are distributed by my former Research institution (Inst)
Travel, Accommodations, Expenses - Abbvie (Inst); Gilead Sciences (Inst); Lilly (Inst); Sanofi (Inst)